Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
The benefit-risk balance must be carefully weighed, including the relapse-free survival (RFS), distant metastasis-free survival (DMFS) and rate of severe immune-related adverse events (irAE) occurrence. Other therapeutic strategies should be investigated in larger studies to confirm the potential limited clinical benefit of this treatment strategy.
Authors
- Julie Cassecuel
- Amir Khammari (ORCID: https://orcid.org/0000-0001-9328-8004)
- Brigitte Dréno (ORCID: https://orcid.org/0000-0001-5574-5825)
- A. Dompmartin (ORCID: https://orcid.org/0000-0003-0081-500X)
- M.‐T. Leccia (ORCID: https://orcid.org/0000-0003-1222-0396)
- J.-M. L’Orphelin (ORCID: https://orcid.org/0000-0002-5680-7888)
- G. Jeudy (ORCID: https://orcid.org/0009-0003-7065-9097)
- Henri Montaudié (ORCID: https://orcid.org/0000-0002-0528-4829)
- F. Brunet‐Possenti (ORCID: https://orcid.org/0000-0003-2100-2913)
- Justine Lavaud
- Florent Grange (ORCID: https://orcid.org/0000-0003-3387-0283)
- Gaelle Quereux (ORCID: https://orcid.org/0000-0002-1739-1701)
- Romain Levard (ORCID: https://orcid.org/0009-0006-6349-8952)
- Dramane Sanogo
Institutions
- Inserm (FR)
- Université Côte d'Azur (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Normandie Université (FR)
- Centre François Baclesse (FR)
- Centre Hospitalier de Valence (FR)
- Maison des Sciences sociales et des Humanités de Dijon (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Université de Limoges (FR)
- Université Grenoble Alpes (FR)
- Nantes Université (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1111/jdv.70136
- Citations
- 1
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.05